Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.57 |
| ▸ | ARG2 | P78540 | 4/20 | 0.52 |
| ▸ | ARG1 | P05089 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 5/20 | 0.46 |
| ▸ | NOS1 | P29475 | 3/20 | 0.46 |
| ▸ | NOS3 | P29474 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2548695 | 1.00 | GSR (0.57) | GSRARG2ARG1CYP1A2CYP2C19 | |
| SCHEMBL2546200 | 1.00 | GSR (0.57) | GSRARG2ARG1CYP1A2CYP2C19 | |
| SCHEMBL2547204 | 0.98 | GSR (0.55) | GSRARG2ARG1CYP1A2CYP2C19 | |
| SCHEMBL2549431 | 0.98 | GSR (0.55) | GSRARG2ARG1CYP1A2CYP2C19 | |
| SCHEMBL2547202 | 0.98 | GSR (0.55) | GSRARG2ARG1CYP1A2CYP2C19 | |
| SCHEMBL600686 | 0.94 | GSR (0.54) | GSRARG2ARG1CYP1A2CYP2C19 | |
| SCHEMBL2548396 | 0.94 | GSR (0.54) | GSRARG2ARG1CYP1A2CYP2C19 | |
| SCHEMBL600685 | 0.94 | GSR (0.54) | GSRARG2ARG1CYP1A2CYP2C19 | |
| SCHEMBL28949518 | 0.86 | GSR (0.47) | GSRARG2ARG1CYP1A2CYP2C19 | |
| SCHEMBL28949516 | 0.86 | GSR (0.47) | GSRARG2ARG1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637686-B2 | Triazole macrocycle systems | AILERON THERAPEUTICS, INC. (US) | 2014-01-28 | — | — | US | claimed |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2011-10-27 | — | — | US | claimed |
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724459-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Peptidream Inc (JP) | 2026-04-15 | — | — | EP | disclosed |
| US-20260098061-A1 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | PEPTIDREAM INC (JP) | 2026-04-09 | — | — | US | disclosed |
| EP-4722228-A1 | NEW COMPOUND TARGETING MUSK AND USE THEREOF | The University of Tokyo (JP) | 2026-04-08 | — | — | EP | disclosed |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | GENEFRONTIER CORPORATION (JP) | 2026-03-03 | — | — | US | disclosed |
| WO-2024254339-A9 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250320471-A1 | Method for Producing Compounds, Method for Producing Compound Library, Compound Library, and Screening Method | UNIV TOKYO (JP) | 2025-10-16 | — | — | US | disclosed |
| EP-4594337-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING EPHRIN TYPE-A RECEPTOR 2 AND USES THEREOF | Rayzebio, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-4594336-A2 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | PeptiDream Inc. (JP) | 2025-08-06 | — | — | EP | disclosed |
| EP-3059244-A1 | C-MET PROTEIN AGONIST | The University of Tokyo (JP) | 2016-08-24 | — | — | EP | disclosed |
| US-20160237119-A1 | C-Met Protein Agonist | THE UNIVERSITY OF TOKYO (JP) | 2016-08-18 | — | — | US | disclosed |
| US-20160209421-A1 | Macrocyclic Peptide, Method for Producing Same, and Screening Method Using Macrocyclic Peptide Library | THE UNIVERSITY OF TOKYO (JP) | 2016-07-21 | — | — | US | disclosed |
| EP-3040417-A1 | MACROCYCLIC PEPTIDE, METHOD FOR PRODUCING SAME, AND SCREENING METHOD USING MACROCYCLIC PEPTIDE LIBRARY | The University of Tokyo (JP) | 2016-07-06 | — | — | EP | disclosed |
| US-20160083719-A1 | Method for Producing Compound Containing Heterocycle | THE UNIVERSITY OF TOKYO (JP) | 2016-03-24 | — | — | US | disclosed |
| EP-2966174-A1 | METHOD OF PRODUCING COMPOUND CONTAINING HETEROCYCLE | The University of Tokyo (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-20150299258-A1 | Peptide for Inhibiting Vascular Endothelial Growth Factor Receptor | THE UNIVERSITY OF TOKYO (JP) | 2015-10-22 | — | — | US | disclosed |
| WO-2015153761-A2 | MACROCYCLIC PEPTIDOMIMETICS FOR ALPHA-HELIX MIMICRY | UNIVERSITY OF ROCHESTER (US) | 2015-10-08 | — | — | WO | disclosed |
| EP-2894161-A1 | PEPTIDE FOR INHIBITING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR | The University of Tokyo (JP) | 2015-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299258-A1 | Peptide for Inhibiting Vascular Endothelial Growth Factor Receptor | KDR, FLT4, TEK | GSR 4479/4885ARG2 1819/4885ARG1 885/4885 |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | CXCL10, MLX, MICA | GSR 4749/4885ARG2 469/4885ARG1 61/4885 |
| US-20160083719-A1 | Method for Producing Compound Containing Heterocycle | VIP, DNPEP, PREP | GSR 2442/4885ARG2 1333/4885ARG1 1905/4885 |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | FLT3, VIP, NGLY1 | GSR 3683/4885ARG2 219/4885ARG1 108/4885 |
| US-20160209421-A1 | Macrocyclic Peptide, Method for Producing Same, and Screening Method Using Macrocyclic Peptide Library | VIP, SLC7A1, PITRM1 | GSR 2520/4885ARG2 32/4885ARG1 398/4885 |
| US-20260098061-A1 | EPHA2-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | EPHA2, EPHA1, EPHB1 | GSR 4580/4885ARG2 4640/4885ARG1 4144/4885 |
| US-20160237119-A1 | C-Met Protein Agonist | MET, HGF, GPR174 | GSR 4636/4885ARG2 3586/4885ARG1 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.